Deseret Mutual Benefit Administrators Sells 2,474 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Deseret Mutual Benefit Administrators trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,141 shares of the biopharmaceutical company’s stock after selling 2,474 shares during the period. Gilead Sciences makes up approximately 0.8% of Deseret Mutual Benefit Administrators’ investment portfolio, making the stock its 22nd largest position. Deseret Mutual Benefit Administrators’ holdings in Gilead Sciences were worth $1,521,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in GILD. CarsonAllaria Wealth Management Ltd. increased its position in Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares in the last quarter. nVerses Capital LLC bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $25,000. Valued Wealth Advisors LLC raised its position in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares during the last quarter. Cedar Wealth Management LLC lifted its stake in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 160 shares during the period. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the 2nd quarter valued at approximately $33,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $93.50 on Thursday. The company has a market capitalization of $116.41 billion, a PE ratio of 111.82, a price-to-earnings-growth ratio of 3.13 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $93.50. The company has a 50-day simple moving average of $84.58 and a 200 day simple moving average of $74.67.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the business posted $2.29 EPS. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, research analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Insider Activity

In related news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock valued at $3,033,340 in the last 90 days. Insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, October 9th. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their target price for the company from $74.00 to $96.00 in a research report on Monday, October 21st. Barclays boosted their price target on Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 price objective on shares of Gilead Sciences in a research report on Monday, September 16th. Ten equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.85.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.